Biotechnology
Ivantis Announces 3 Year Results of Australian SPECTRUM Registry for Hydrus Microstent
Largest Set of MIGS Data Ever Produced in Australia Includes Over 900 Eyes with 200+ Stand-Alone Glaucoma Procedures IRVINE, California, Nov. 8, 2019 /PRNewswire/ -- Ivantis today announced long term results of the Australian cohort of the Global SPECTRUM registry. SPECTRUM is a post market pati...
2019-11-08 03:00
525
Enzene Opens its First Continuous Biologics Manufacturing Facility With a Promise to Disrupt the mAb Manufacturing Cost
PUNE, India, Nov. 7, 2019 /PRNewswire/ -- Enzene Biosciences today formally opened its first fully connected continuous Biologics manufacturing facility in Pune, India. This first-of-its-kind facility was built in half the time as compared to the conventional biologics manufacturing plants. The s...
2019-11-07 20:24
353
TransThera Biosciences Lead Product TT-00420 Granted Orphan Drug Designation from FDA to Treat Cholangiocarcinoma
NANJING, China, Nov. 7, 2019 /PRNewswire/ -- TransThera Biosciences Co. Ltd, announced today that company received Orphan Drug Designation from US Food and Drug Administration (FDA) for TT-00420, a clinical stage investigational drug, for the treatment of cholangiocarcinoma. Dr. Frank Wu, Founde...
2019-11-07 20:08
272
WuXi AppTec Receives Investment Grade Corporate Ratings from Three Global Rating Agencies
SHANGHAI, Nov. 6, 2019 /PRNewswire/ -- WuXi AppTec announced today that it has received investment grade corporate credit ratings from three global rating agencies: Moody's (Baa3), S&P Global Ratings (BBB-), and Fitch Ratings (BBB-); all three agencies maintain a stable outlook on WuXi AppTec. Th...
2019-11-06 16:00
240
China Biologic Products to Report Third Quarter 2019 Financial Results
BEIJING, Nov. 4, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its third quarter 2019 financial results o...
2019-11-04 21:30
6055
Mallinckrodt and Terumo BCT Announce UVADEX® (Methoxsalen) Approved in Australia for use with the THERAKOS® CELLEX® Photopheresis System for the Treatment of Chronic Graft Versus Host Disease (cGvHD) and Skin Manifestations of Cutaneous T-Cell Lymphoma (CTCL) in Adults
SYDNEY, Nov. 1, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, and Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, today announced that UVADEX® (methoxsalen) has received regulatory approval inAustralia by th...
2019-11-01 04:35
5528
Icon Group Expands Cancer Care Capabilities with Purchase of Varian Adaptive Therapy Solution
PALO ALTO, California, Oct. 31, 2019 /PRNewswire/ -- Icon Group, Australia's largest dedicated provider of cancer care, with a growing reach intoNew Zealand andAsia, has made a purchase order to further improve the quality of cancer care treatment across its international network. The order inc...
2019-10-31 04:05
5183
Arena Pharmaceuticals Announces First Subject Dosed in ADVISE Phase 2 Trial Evaluating Etrasimod in Atopic Dermatitis
- ADVISE clinical trial initiated and enrollment progressing - Evaluating patients with the clinical diagnosis of moderate-to-severe atopic dermatitis - Significant unmet need for an oral therapy in atopic dermatitis SAN DIEGO, Oct. 28, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ...
2019-10-28 20:30
2549
HistoIndex Announces Global Partnerships To Expand AI-Based Digital Pathology Platform As A Drug Discovery Tool In Preclinical Studies For Nonalcoholic Steatohepatitis (NASH)
SINGAPORE, Oct. 26, 2019 /PRNewswire/ -- HistoIndex
2019-10-26 19:00
495
Adagene Presents Its Lead Antibody Program, ADG106, at International Conferences
SAN FRANCISCO and SUZHOU, China, Oct. 26, 2019 /PRNewswire/ -- Adagene, Inc., a clinical stage biotech company with innovative antibody discovery and engineering technologies, announced that it is presenting its lead program at international conferences. During the Festival of Biologics confere...
2019-10-26 18:01
568
Happiness Biotech Group Limited Announces Pricing of US$11 Million Firm Commitment Initial Public Offering
NANPING, China, Oct. 25, 2019 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company"), an innovativeChina-based nutraceutical and dietary supplements producer,announced today the pricing of a U.S. underwritten initial public offering ("Offering") of 2,000,000 ordinary shares at a price to...
2019-10-25 22:00
7712
New Horizon Health and Prenetics Establish Strategic Partnership to Launch ColoClear, the Chinese rival to ColoGuard, in Hong Kong and Southeast Asia
* ColoGuard, owned by Exact Sciences is one of the most successful genomics companies in the World, currently listed on the Nasdaq with a market cap ofUSD 12 Billion. * ColoClear will be the region's 1st non-invasive DNA stool test to screen for colorectal cancer at 92%,which can be done in t...
2019-10-21 20:00
266
China Biologic Special Committee Retains Financial Advisor and Legal Counsel
BEIJING, Oct. 17, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the special committee (the "Special Committee") of the Company's board o...
2019-10-17 20:00
9946
Sirtex Medical appoints Kevin R. Smith as Chief Executive Officer
Interim CEO unanimously chosen to lead global operations in patient-first oncology innovation WOBURN, Mass., Oct. 16, 2019 /PRNewswire/ -- Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced the appointment ofKevin R. Smith as Chief Executive Officer of Sir...
2019-10-16 22:00
655
The 26th China Yangling Agricultural High-tech Achievements Expo will begin on October 22
YANGLING, China, Oct. 16, 2019 /PRNewswire/ -- On October 15, over ten international reporters, representing, among others, the European Pressphoto Agency, the Colpisa News Agency, the Korean Central News Agency, Radio-Television Slovenia, and the Republic of Korea's "Asian Economy", visited Yan...
2019-10-16 19:28
274
WuXi AppTec Research Service Division and BioSolveIT Introduce GalaXi®, a Vast New Chemical Space of Tangible Molecules
SHANGHAI and CAMBRIDGE, Massachusetts and SANKT AUGUSTIN, Germany, Oct. 10, 2019 /PRNewswire/ -- WuXi AppTec Research Service Division and BioSolveIT today launched a new virtual chemical space called GalaXi®. Largely built from WuXi AppTec's library of novel drug-like scaffolds, GalaXi® offers a...
2019-10-11 08:02
6041
Medicago's New Drug Submission accepted for scientific review by Health Canada: An important step for Medicago towards commercialization of its innovative influenza vaccine
QUEBEC CITY, Oct. 3, 2019 /PRNewswire/ -- Medicago, a biotechnology company and global leader in the development and production of plant-derived vaccines with headquarters inQuebec City, announces today that Health Canada accepted for scientific review its New Drug Submission (NDS) for a plant-ba...
2019-10-03 06:30
412
Kinoxis Therapeutics Awarded NIH HEAL Initiative Grant to Advance KNX100 for the Treatment of Opioid Withdrawal
MELBOURNE, Australia and SYDNEY, Sept. 29, 2019 /PRNewswire/ -- Kinoxis Therapeutics Pty Ltd, a pre-clinical stage biotechnology company developing novel therapies for substance use disorders and other central nervous system disorders, has been awarded a major grant from the US National Institut...
2019-09-30 05:00
301
Preclincal Results of Baoyuan's Next-Generation ROS1/NTRK Inhibitor AB-106 Published in Nature Communications
HANGZHOU, China, Sept. 25, 2019 /PRNewswire/ -- The preclinical results of AB-106 (original code: DS-6051b), an investigational next generation ROS1/NTRK dual inhibitor exclusively in-licensed by AnHeart Therapeutics, a wholly-owned subsidiary of Baoyuan Biopharmaceuticals Technology (Hangzhou) C...
2019-09-25 18:35
768
China Biologic Forms Special Committee to Review "Going Private" Proposal
BEIJING, Sept. 24, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that its board of directors (the "Board") has formed a special committee (th...
2019-09-24 20:00
11282
Week's Top Stories
Most Reposted
Wirecard Expands Its Global Financial Platform Services with Market Entry Into China, Investing in Licenses for Digital Payments
[Picked up by 110 media titles]
2019-11-05 22:26NTT Launches MYNAP - Malaysia's Next Internet Exchange
[Picked up by 110 media titles]
2019-11-06 08:52
Comdex Completes Over $10M Worth of Commodity Trade Processes
[Picked up by 102 media titles]
2019-11-08 15:08Xinhua Silk Road: Deals worth over RMB30 bln signed at Zhangjiagang autumn economic and trade week
[Picked up by 102 media titles]
2019-11-06 18:50PressReader brings entertainment to new heights with JetBlue partnership
[Picked up by 96 media titles]
2019-11-07 03:25
Most Read
JNA Awards 2020 continues to receive strong endorsement from industry leaders
2019-11-07 16:35
12381
Frost & Sullivan Distinguishes Inovalon as Company of the Year for Advancing the Healthcare Industry by Harnessing Massive-Scale Data and Advanced Analytics
2019-11-05 22:00
5799
Vipshop to Announce Third Quarter 2019 Financial Results
2019-11-05 18:00
5355